UNAUDITED FINANCIAL RESULT FOR THE QUARTER ENDED ON 31.12.2025
Awaiting price reaction for this filing.
Citurgia Biochemicals reported no revenue from operations or other income for the third quarter of FY26, with the company essentially in a non-operating state. Total expenses for the quarter stood at ₹28.84 lakhs, comprising employee costs (₹4.40 lakhs), depreciation (₹5.73 lakhs), and other expenses (₹18.71 lakhs). This resulted in a net loss of ₹28.84 lakhs for Q3, widening from ₹10.43 lakhs loss in the year-ago quarter, and a cumulative nine-month loss of ₹47.60 lakhs. EPS was negligible at ₹0.001 for the quarter. The statutory auditor issued a clean limited review report with no qualifications, and there were no pending investor complaints.
The company continues to burn cash with zero revenue and mounting losses, which is a serious red flag for shareholders. Without a revival in operations or new revenue streams, the stock remains highly speculative and risky.